Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives $75.00 Consensus Price Target from Analysts

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has been given an average rating of “Moderate Buy” by the fourteen brokerages that are currently covering the stock, MarketBeat reports. Seven research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $75.00.

Several equities research analysts have issued reports on HALO shares. Wall Street Zen cut Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, November 8th. Zacks Research downgraded Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “hold (c+)” rating to a “buy (b)” rating in a report on Friday, November 7th. Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Tuesday, November 4th. Finally, HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, October 21st.

Halozyme Therapeutics Price Performance

Shares of HALO stock opened at $71.19 on Friday. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01. The company has a market capitalization of $8.37 billion, a PE ratio of 16.29, a price-to-earnings-growth ratio of 0.35 and a beta of 1.18. The firm’s 50-day moving average is $70.37 and its two-hundred day moving average is $63.13. Halozyme Therapeutics has a 12 month low of $42.01 and a 12 month high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.63 by $0.09. The business had revenue of $354.26 million during the quarter, compared to the consensus estimate of $339.18 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The business’s revenue was up 22.1% compared to the same quarter last year. During the same quarter last year, the firm earned $1.27 EPS. Analysts predict that Halozyme Therapeutics will post 4.73 earnings per share for the current year.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $69.13, for a total value of $1,382,600.00. Following the sale, the chief executive officer owned 733,719 shares of the company’s stock, valued at $50,721,994.47. The trade was a 2.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Bernadette Connaughton sold 2,000 shares of the company’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $68.48, for a total value of $136,960.00. Following the transaction, the director owned 42,952 shares in the company, valued at $2,941,352.96. This trade represents a 4.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 110,227 shares of company stock worth $8,028,955. Insiders own 2.90% of the company’s stock.

Hedge Funds Weigh In On Halozyme Therapeutics

Several institutional investors have recently bought and sold shares of HALO. Penserra Capital Management LLC purchased a new position in shares of Halozyme Therapeutics in the first quarter valued at approximately $125,000. Envestnet Asset Management Inc. lifted its holdings in Halozyme Therapeutics by 0.4% during the 1st quarter. Envestnet Asset Management Inc. now owns 303,774 shares of the biopharmaceutical company’s stock worth $19,384,000 after buying an additional 1,161 shares in the last quarter. Nisa Investment Advisors LLC boosted its position in Halozyme Therapeutics by 4.0% in the 1st quarter. Nisa Investment Advisors LLC now owns 5,611 shares of the biopharmaceutical company’s stock valued at $358,000 after buying an additional 215 shares during the period. State of Michigan Retirement System grew its stake in shares of Halozyme Therapeutics by 1.0% in the first quarter. State of Michigan Retirement System now owns 30,438 shares of the biopharmaceutical company’s stock worth $1,942,000 after acquiring an additional 300 shares in the last quarter. Finally, Xponance Inc. increased its position in shares of Halozyme Therapeutics by 1.1% during the first quarter. Xponance Inc. now owns 18,652 shares of the biopharmaceutical company’s stock worth $1,190,000 after acquiring an additional 198 shares during the period. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.